Source: chrupka/Getty Images

FDA Approves Invivoscribe’s CDx for AML Drug Xospata

The LeukoStrat CDx FLT3 Mutation Assay had previously won approval in the U.S. and Europe for Novartis drug Rydapt
Source: ChrisChrisW/Getty Images

Link Found between Mom’s Microbiome and Child’s Risk for Autism

UVA researchers have linked a mother's gut microbiome and maternal immune activation with her child's susceptibility to developing autism
David Huntsman

The National Access Project for Cancer Testing

With unprecedented scientific advances over the last decade in genome sequencing, we now have an opportunity to make genomics testing a standard practice in...
Source: David Wong

Liquid Biopsy Thrusts Non-Invasive Molecular Diagnostics into the Clinical Arena

Watch our free webinar to obtain all of the relevant detailed information that our experts have to offer.
Source: Getty Images

Transgenomic Licenses Genetic Cardiac Test to LabCorp

Transgenomic’s intellectual property enhances LabCorp’s DNA testing for long QT syndrome, a congenital heart rhythm disorder.
Owlstone Medical's Lonestar gas analyzer (pictured with the ReCIVA breath sampler) will be studied in a clinical trial with Mayo Clinic assessing its effectiveness as a test for bowel preparation before colonoscopy. (Source: Owlstone Medical)

Owlstone Medical, Mayo Clinic Plan Trial of FAIMS Platform As Pre-Endoscopic Test

Partners to study Field Asymmetric Ion Mobility Spectrometer as a non-invasive test assessing adequacy of bowel prep before colonoscopies
Source: Alex Belomlinsky/Getty Images

New Collaboration Seeks Improved Breast Cancer Diagnostics

Researchers look to bring more targeted diagnosis and treatment to breast cancer patients in the future.
ersonal Genome Diagnostics (PGDx) said today that its 500+ gene pan-cancer tumor profiling tissue assay is being used by Merck & Co. in a Phase II clinical trial designed to assess patient response to a dual biomarker-directed precision oncology combination therapy in patients with previously untreated advanced non-small cell lung cancer (NSCLC).

Merck Using PGDx Pan-Cancer Tissue Assay in Combination Therapy Trial

Pharma using PGDx’s 500+ gene elio tissue complete assay in Phase II KEYNOTE-495 trial to analyze patients’ tumor mutational burden status.
Healthcare professionals express concern that due to complexities of genetic testing and counseling

Direct-to-Consumer Genetic Testing: Will It Go Away?

The NIH defines direct-to-consumer genetic tests (DTCs) as those aimed at consumers via television, print advertisements, or the Internet. Also known as at-home genetic...
Bristol-Myers Squibb (BMS) plans to use Natera's Signatera custom circulating tumor DNA (ctDNA) assay in a Phase II study designed to assess the pharma giant’s cancer immunotherapy Opdivo (nivolumab) as an adjuvant treatment for non-small cell lung cancer (NSCLC). [Source: Eraxion/Getty]

Biodesix to Acquire Oncimmune’s U.S. Operations

Genomic and proteomic blood-based diagnostics developer Biodesix announced that it will acquire the U.S.-based assets of Oncimmune a U.K.-based cancer immunodiagnostics and biomarker identification...
Scroll Up